|Day Low/High||1.40 / 1.42|
|52 Wk Low/High||0.64 / 5.37|
Study will utilize Afrezza® inhaled insulin and the One Drop digital diabetes care platform
Former hedge funder and biotech CEO Martin Shkreli finds himself in limbo as a criminal jury now decides if allegations of fraud will put him in orange coveralls.
Michael Castagna appointed Chief Executive Officer and Member of MannKind Board of Directors
Conference Call to Begin Today at 5:00 PM ET
Shares of insulin maker Mannkind plummeted on news of a proposed stock split, staffing changes and a new iteration of its insulin.
Mannkind stock is suffering, and the company appears to be in trouble.
Other movers included Mannkind, Perrigo and Bristol-Myers Squibb.
The stock has taken a beating, but users of Afrezza are loyal to the drug.